Indexes and overall tone
Wall Street limped into the weekend looking more like a tired marathoner than a sprinter, as major U.S. equity indexes closed a volatile, tariff‑tossed week with modest moves that felt heavier than the point changes implied. The S&P 500 ended the period with its second straight weekly decline, the Dow industrials slipped again under the weight of old‑economy bellwethers, and the Nasdaq managed to dip slightly too over the course of the week that said more about investors’ reluctance to abandon AI and chip darlings than any broad conviction. Small caps, represented by the Russell 2000, fared a little worse as risk appetite waned, leaving the index lower on the week and reminding traders that not all boats rise in a choppy tide.
Macro backdrop and Fed watch
The macro backdrop was busy for a holiday‑shortened stretch, even if the data did more to refine narratives than to rewrite them. Inflation remained the central preoccupation, with attention firmly trained on consumption and the Fed’s preferred gauges as investors weighed whether price pressures are easing enough to justify rate cuts this year or merely drifting toward a higher‑for‑longer plateau. Forecasts for the Personal Consumption Expenditures readings pointed to month‑over‑month gains around 0.2% and year‑over‑year inflation stuck near 2.8%, a level uncomfortably above the Federal Reserve’s 2% objective and therefore conveniently supportive of officials’ cautious rhetoric. Growth indicators remained mixed: a solid GDP backdrop, resilient labor markets, and expansionary but subdued purchasing managers’ indexes all painted the picture of an economy slowing from a sprint to a controlled jog rather than flirting with recession. Consumer sentiment was expected to hold in the mid‑50s on the University of Michigan index, a reading that suggests households are more resigned than exuberant but not yet in the mood for recessionary storytelling.
Rates, yield curve and FOMC expectations
Monetary policy, never far from the market’s mind, loomed large in the background as traders looked ahead to the next’s Jan. 27-28 Federal Open Market Committee (FOMC) gathering, widely expected to result in another “hold‑and‑watch” decision rather than a dramatic pivot. With inflation still running above target and growth not yet cracking, futures markets continued to price in a cautious path of eventual easing, while policymakers signaled that restrictive settings could persist longer than investors would prefer but shorter than the bond market’s more pessimistic scenarios once advertised. The yield curve stayed compressed, with shorter‑dated rates anchored by Fed expectations and longer‑term yields reflecting a blend of inflation uncertainty and term premium, a structure that still whispers late‑cycle rather than early‑recovery.
Tariffs and trade policy
Trade policy took another turn on the geopolitical stage, where tariffs once again auditioned for the role of main antagonist before being asked to stand down—for now. President Trump moved to pause a planned 10% levy on imports from eight NATO allies, offering markets a brief sigh of relief and a reprieve from what had threatened to be another front in the global trade skirmishes. Anxiety around tariffs on European goods faded somewhat as the week progressed, but not enough to restore full risk‑on cheer, particularly with tensions between Washington and European capitals still simmering over strategic assets and influence.
Greenland and geopolitics
The Greenland saga, which might have looked like geopolitical fan fiction a few years ago, continued to cast a peculiar shadow over asset markets. The administration touted a “framework” for a deal around Greenland‑related interests, keeping investors attentive to the intersection of Arctic resources, European relations, and U.S. strategic ambitions. Meanwhile, tensions over U.S.–European control and influence around Greenland and nearby strategic zones remained a recurring theme in foreign‑policy commentary, adding yet another non‑economic variable into models already juggling inflation, growth, and policy risk.
Commodities and bitcoin
In the commodities complex, gold decided subtlety was overrated. The metal surged to fresh record highs, briefly topping the 4,900‑dollar‑per‑ounce mark and logging its best week since 2020 as a weaker dollar, & actually hit $4,989.90 just under the 5k mark as geopolitical jitters, and doubts about the durability of disinflation stoked safe‑haven demand. Silver, not to be outdone, crossed the psychologically loud 100‑dollar threshold closing at $103.36/oz., underscoring just how far the precious‑metals trade has run in a world rediscovering hedges against both inflation and political uncertainty. Oil prices edged 1.56% higher this week to $61.28/bbl as traders weighed President Trump’s remarks about a Greenland‑related “framework” and broader cross‑Atlantic tensions, signaling that crude remains a convenient vessel for pricing geopolitical unease as much as physical supply and demand. Bitcoin trading around $89.5K, for its part, remained a lightning rod for speculation and macro narratives, trading as a high‑beta proxy on liquidity expectations and risk sentiment even as traditional safe havens stole the week’s spotlight.
Eli Lilly and big pharma
On the corporate front, Eli Lilly (LLY, $1,064.29, +3.03% over the last 5-days) continued to behave more like a marquee tech name than a staid pharmaceutical concern. Shares climbed this week, helped by the U.S. Food and Drug Administration granting Breakthrough Therapy designation to sofetabart mipitecan, an oncology candidate for a subset of ovarian cancer patients, reinforcing the company’s reputation as a central player in both obesity and cancer therapeutics. Analysts kept up a drumbeat of bullishness, with estimates and coverage reiterating the view that Lilly’s earnings trajectory and drug pipeline justify its lofty valuation and trillion‑dollar market capitalization, even if shorter‑term volatility occasionally reminds investors that gravity has not been formally repealed.
Chips, AI hardware and foundries
The semiconductor and AI hardware narrative remained dominated by a familiar cast of characters, with Taiwan Semiconductor Manufacturing Company, Nvidia, Apple, Micron, Broadcom, and Intel all central to the week’s conversations. TSMC’s role as the indispensable foundry to Nvidia (NVDA, $187.67, +.33% over the last 5-days), Apple, and other chip leaders was once again underscored, with the company’s ongoing multibillion‑dollar expansion in Arizona seen as both a hedge against geopolitical risk and a vote of confidence in the long‑term AI and high‑performance‑computing boom. Nvidia retained its status as the poster child of AI infrastructure, with fresh analyst commentary highlighting its dominant share of data center accelerators and raising price targets on the premise that trillions of dollars in AI‑related capex are still ahead. Micron (MU, $399.65, +18.72% over the last 5-days), riding the coattails of insatiable AI memory demand, enjoyed continued enthusiasm as rising DRAM prices and long‑term supply contracts reinforced the notion that the memory cycle has turned decisively in its favor. Broadcom, meanwhile, stayed in the frame as a critical enabler of AI networking and custom chips, benefiting from its position at the heart of data center plumbing even as investors debated just how long the current spending cycle can persist.
Intel and earnings disappointments
Intel (INTC, $45.07, -6.73% over the last 5-days) had a more complicated week, with the stock sliding after earnings disappointed investors who had come to expect a cleaner turnaround narrative from the once‑dominant chipmaker. The company’s soft results, coupled with cautious guidance, weighed on the broader Dow and tech complex, reminding markets that not every player in the AI ecosystem is benefiting equally from the current wave of spending. At the same time, some commentary pointed out that Intel’s recent rally had left it vulnerable to even modest underperformance, and the reaction may have reflected expectations as much as fundamentals.
Big Tech, EVs and software names
Big Tech and adjacent names continued to command attention. Apple remained a core holding in many AI‑and‑ecosystem portfolios, with its role as both a device maker and potential beneficiary of on‑device intelligence keeping it central to discussions about the next leg of tech hardware demand. Meta stayed in focus as investors weighed its heavy AI infrastructure spending against the durability of its advertising franchise and the potential upside of new monetization initiatives. Tesla remained a lightning rod, with attention on its progress in autonomous driving and new services—such as expanded robotaxi offerings—helping to sustain speculative interest despite ongoing questions about growth, competition, and margins. Palantir continued to be cast as a high‑growth software name at the intersection of AI and data analytics, with deals and long‑term contracts feeding expectations of continued revenue expansion and a maturing commercial business. Tesla (TSLA, $449.06, +2.39%) as Elon Musk spoke positively at Davos about robot axis and beyond.
Networks, cloud, nuclear and prop‑tech
Beyond the mega‑caps, the broader technology and digital‑economy cohort offered its own color. Nokia (NOK, $6.77., +2.42% over the last 5-days) stayed part of the conversation around network infrastructure and 5G‑and‑beyond deployments, a space that benefits from rising data consumption but has to wrestle with cyclical carrier spending. Oracle featured in discussions about cloud and enterprise software, as investors weighed its position in databases and infrastructure‑as‑a‑service against larger rivals in an increasingly AI‑centric IT spending landscape. Oklo, representative of the new generation of nuclear‑technology developers, continued to draw attention from investors looking for long‑duration plays on clean baseload power, even as regulatory and financing hurdles remained front and center. Opendoor, emblematic of prop‑tech’s attempt to algorithmically tame the housing market, sat at the intersection of real‑estate cycles, interest rates, and investor tolerance for business models that depend on liquidity and price stability in historically volatile assets.
Defensives and cyclicals: McDonald’s and Rio Tinto
Outside of tech and healthcare, stalwarts like McDonald’s (MCD, $309.25, +.20%) and Rio Tinto (RIO, $90.43, +4.73%) reminded markets that cash‑flow reliability still has an audience. McDonald’s remained a defensive favorite, with its global footprint and pricing power offering investors a way to participate in consumer spending without betting heavily on the most economically sensitive categories. Rio Tinto, by contrast, provided exposure to industrial metals I.e. copper that hit new highs, and global growth expectations, its fortunes closely tied to both Chinese demand and broader infrastructure‑and‑energy transitions.
Deals, M&A and IPO mood
In dealmaking, the week delivered at least one headline to remind investors that corporate strategists have not entirely gone into hibernation. Capital One announced an agreement to acquire corporate‑card and spend‑management platform Brex for roughly 5 billion dollars, a price that represents a sharp discount to the start‑up’s peak private‑market valuation and a telling snapshot of how the late‑cycle funding boom has deflated. The transaction highlighted how established financial institutions are still using acquisitions to buy technology and new customer relationships, while founders and early investors in high‑growth fintechs are being introduced to the concept of “downside scenarios” the hard way.
In the primary markets, the pipeline for initial public offerings on the New York Stock Exchange and Nasdaq remained active but selective, with investors showing renewed interest in companies tied to AI and chips while maintaining a more cautious stance toward businesses that lack clear profitability paths. Activity continued to be shaped by the same calculus that has dominated since the last cycle’s froth faded: firms with strong cash flows, defensible niches, or direct links to AI and data infrastructure can find a receptive audience, while others are encouraged—politely—to wait for better conditions.
Closing perspective
Taken together, the week ending January 23, 2026, offered a familiar but still engrossing script: equity indexes grinding lower even as certain themes—AI hardware, weight‑loss and oncology drugs, safe‑haven metals—enjoyed star billing. The market, it seems, remains perfectly capable of worrying about tariffs, Greenland, inflation, and earnings all at once, even as investors continue to pay up for growth stories that promise to turn today’s volatility into tomorrow’s compounded returns.
Vista Partners Watchlist Updates
Modular Medical, Inc. (Nasdaq: MODD., $.4667), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, announced (Dec. 10) that it had priced an underwritten public offering (the “offering”) of 12,173,000 shares of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock. Each two shares of common stock are being offered and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance. In connection with the offering, Modular Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of common shares and/or warrants at the public offering price, less underwriting discounts and commissions. The over-allotment option may be elected with respect to, at the underwriter’s sole discretion, shares and warrants together, solely shares, solely warrants, or any combination thereof. Newbridge Securities Corporation is acting as the sole bookrunner for the offering. Assuming no exercise of the over-allotment option, the gross proceeds to the Company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts, commissions, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures.
On Nov. 17, Modular announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.
On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $9, up 2.62% over the last 5-days), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated,“These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”
GeoVax Labs, Inc. (Nasdaq: GOVX, $3.15, +10.53% over the last 5-days), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer.
GeoVax is heading into the 44th Annual J.P. Morgan Healthcare Conference week (“JPM2026”) in San Francisco, CA Jan. 12-15 with the kind of narrative biotech investors typically like to hear: a differentiated platform, large funded trials lining up, and multiple shots on goal in both infectious disease and oncology. The company is leaning into its MVA platform as a potential franchise engine rather than a one‑product science experiment. Specifically, investors can meet David Dodd, Chairman & CEO of GeoVax, during his presentation at the Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA on January 13, 2026, 2:30 pm PST.
GeoVax announced (Dec. 19) that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $3.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 22, 2025, subject to the satisfaction of customary closing conditions.
GeoVax announced (Dec. 18) the publication of a peer-reviewed article in Frontiers in Immunology titled: “Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.” The study provides definitive preclinical evidence that GeoVax’s multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, delivers full cross-variant protection, driven predominantly by robust T-cell responses, even in the absence of neutralizing antibodies. The findings reinforce the design philosophy behind GeoVax’s MVA-based, multi-antigen platform and provide mechanistic insight that is increasingly relevant for immunocompromised individuals, who often fail to respond optimally to the first-generation COVID-19 vaccines.
GeoVax announced (Dec. 17) the successful completion of fill-finish for the initial clinical batch of GEO-MVA, its next-generation Mpox/smallpox vaccine. The product has now entered final release evaluation, the concluding quality-control and compliance process required before shipment for clinical use, positioning the Company for Phase 3 immunobridging trial start-up activities in Q1 2026. Fill-finish – the sterile, cGMP-regulated process of filling, sealing, and packaging vaccine vials – marks the last manufacturing step before a vaccine may enter clinical study supply channels. With fill-finish complete and GEO-MVA now undergoing final release evaluation, GeoVax has moved into the final pre-clinical-deployment phase of its EMA-aligned clinical program. In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex(R), would be sufficient to evaluate GEO-MVA’s efficacy. This provides a clear, accelerated regulatory path to licensure. This milestone coincides with increasing Mpox activity globally – including expanding Clade I outbreaks in Africa and emerging cases in the United States – exposing vulnerabilities associated with global dependence on a sole foreign MVA vaccine supplier. GEO-MVA is designed to expand supply, diversify sources, and strengthen biodefense infrastructure.
Volato Group, Inc. (NYSE American: SOAR, $.49) and M2i Global, Inc. (MTWO, $.0485), a company specializing in the development and execution of a complete global value supply chain for critical minerals, reaffirmed, on Tuesday, Jan. 20, their expectation to complete their targeted first-quarter 2026 closing timeline for the previously announced business combination, citing steady advancement through the SEC review process alongside continued progress in operational planning and integration readiness. Subject to the effectiveness of the registration statement on Form S-4, stockholder approvals, and other customary closing conditions, the companies continue to expect the merger to close in the first quarter of 2026. To align the transaction timeline with the current stage of the SEC review process, the companies have mutually agreed to extend the end date of the merger agreement through March 31, 2026. This extension reflects disciplined execution and provides additional runway to complete the remaining regulatory steps in an orderly manner, while maintaining transaction commitment and protecting stockholder interests. Amendment No. 1 to the Form S-4 was filed on Monday, January 12, 2026, to respond to SEC comments and advance the registration statement through the review process. The review timeline was affected in part by a temporary slowdown in SEC operations following the recent federal government shutdown. With the amendment now on file, the companies are focused on completing the remaining steps of the SEC review process.
On Jan. 9, M2i Global and Volato Group announced that they have entered into a strategic collaboration agreement with Australian company Titanium X to advance critical mineral development in the US. This partnership represents a significant move towards enhancing domestic refining capacity and strengthening the critical materials supply chain that underpins US industry and national security. Titanium X and M2i Global will work together on the financing, development and commercialisation of the former’s critical mineral assets. M2i Global will apply its global experience in delivering mineral projects to support these initiatives. The companies are also in talks to conclude an exclusive titanium concentrate supply agreement.
On Jan. 7, M2i Global, Inc. (MTWO , $,05) along with Volato Group, Inc. (NYSE American: SOAR, $.45), a technology-driven company, announced a strategic collaboration agreement with Titanium X, marking a major step forward in advancing domestic refining capabilities and securing the critical materials supply chain essential to U.S. industry and national security.
Volato Group, Inc. today (Dec. 29) announced the appointment of Alan D. Gaines to its Board of Directors, effective immediately. Mr. Gaines will also serve as Chairman of the Audit Committee.
On Dec. 23, Volato Group, Inc. announced preliminary financial guidance for the fourth quarter and full year ending December 31, 2025, reflecting continued execution against its strategic and balance sheet objectives. For the fourth quarter of 2025, Volato expects to report revenue between $27 million and $28 million. For the full year 2025, the Company anticipates total revenue between $78 million and $79 million, with net income of $6 million to $8 million. These results reflect a year of meaningful progression aligning operational performance with Volato’s long-term growth initiatives and advancing its pending merger with M2i Global, Inc. (OTC: MTWO). During 2025, Volato also made substantial progress strengthening its balance sheet. As of September 30, 2025, the Company reduced total liabilities to $9.5 million, satisfying the debt reduction condition required under its pending merger agreement with M2i Global, Inc. (OTC: MTWO). Volato expects continued improvement in its capital structure as it advances toward a targeted first-quarter 2026 closing of the transaction. “Our 2025 results reflect a year of transformation and disciplined balance sheet execution,” said Mark Heinen, Chief Financial Officer of Volato. “We made significant progress reducing liabilities while sharpening our focus on scalable, technology-driven businesses that are designed to complement and strengthen the M2i Global platform over the long term.”
Serina Therapeutics (NYSE American: SER, $2.87), Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies. On Dec. 11, Serina announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development.
On Dec. 10, Serina announced that it has submitted a complete response to the U.S. Food and Drug Administration’s (“FDA”) clinical hold letter for SER-252, the Company’s lead program for advanced Parkinson’s disease. As previously disclosed, the FDA placed the Company’s Investigational New Drug (“IND”) application for SER-252 on clinical hold pending additional information related to a commonly used formulation excipient. On November 25, 2025, the FDA issued a formal full clinical hold letter specifying the information required to permit initiation of the planned Phase 1b registrational study, SER-252-1b. The issues identified by the FDA do not relate to the apomorphine active drug substance, its mechanism of action, the use of the enFuse device (Enable Injections) or the broader 505(b)(2) NDA development pathway previously discussed with the Agency.
The InterGroup Corporation (NASDAQ: INTG, $29.87, +1.67%) announced (Jan. 6) that on December 29, 2025, it completed the sale of a non-core 12-unit apartment complex in Los Angeles County for a gross sales price of approximately $4,850,000. InterGroup expects to report a GAAP net gain on sale of approximately $3,509,000, which will be reflected in the Company’s Form 10‑Q for the quarter ended December 31, 2025. The transaction is expected to result in federal and state income tax liability, the amount of which will be determined based on the Company’s final tax position and applicable tax rules.
DoubleVerify Holdings Inc. (DV) closed at $10.99, +4.07% over the last 5-days. DoubleVerify, which built its franchise on media verification and ad performance analytics, is now the first badged TikTok Marketing Partner focused specifically on attention measurement, tapping impression-level signals from the platform. Brands gain a granular view of how exposure and user interaction come together across TikTok formats, ad sets, creatives, and objectives, effectively treating every swipe as a tiny A/B test.
flyExclusive, Inc. (NYSE American: FLYX, $3.28), one of the nation’s largest private jet operators and a certified Part 145 Repair Station, today announced it has signed an authorized dealership agreement with Starlink, becoming a certified dealer and installer for Starlink’s high-speed, low-latency aviation connectivity system.
The Sources
- Wall Street Journal – “Stock Market Today: Dow Drops; Intel Stock Slides; Gold Hits Record”
https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-23-2026[wsj] - Bloomberg – “S&P 500 Steady at End of Turbulent Week; Intel Sinks on Earnings”
https://www.bloomberg.com/news/articles/2026-01-23/us-stocks-slip-at-end-of-turbulent-week-intel-sinks-on-earnings[bloomberg] - Bloomberg – “S&P 500 Posts Its First Two-Week Losses Since June: Markets Wrap”
https://www.bloomberg.com/news/articles/2026-01-22/stock-market-today-dow-s-p-live-updates[bloomberg] - Yahoo Finance – “Stock market today: Dow, S&P 500, Nasdaq rise after Trump backpedals on tariffs”
https://finance.yahoo.com/news/stock-market-today-dow-sp-500-nasdaq-futures-rise-after-trump-backpedals-on-tariffs-234947394.html[uk.finance.yahoo] - Reuters – “Wall Street finishes up as investors buoyed by tariff relief, upbeat data”
https://www.reuters.com/world/europe/futures-rise-further-greenland-relief-2026-01-22/[reuters] - New York Times – “Stocks Rebound After Trump Backs Off European Tariffs”
https://www.nytimes.com/2026/01/21/business/greenland-stocks-bonds-dollar-gold.html[nytimes] - U.S. News & World Report – “US Stocks Recover Half of the Prior Day’s Plunge After Trump Calls off Greenland-Related Tariffs”
https://www.usnews.com/news/business/articles/2026-01-20/us-stocks-recover-half-of-the-prior-days-plunge-after-trump-calls-off-greenland-related-tariffs[usnews] - Investopedia – “Markets News, Jan. 22, 2026: Stocks Finish Higher for 2nd Straight Day”
https://www.investopedia.com/dow-jones-today-01222026-11890213[investopedia] - Investors.com – “Dow Falls While Nasdaq Is The Day’s Bright Spot (Live Coverage)”
https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-greenland-deal-intel-stock-intc/[investors] - Investors.com – “Stock Market Falls, Recovers On Trump Greenland Shift” (Weekly Review)
https://www.investors.com/news/stock-market-falls-recovers-on-trumps-greenland-shifts-intel-netflix-tesla-key-movers-weekly-review/[investors] - CNBC – “5 things to know before the stock market opens Friday” (Jan. 23, 2026)
https://www.cnbc.com/2026/01/23/5-things-to-know-before-the-stock-market-opens.html[cnbc] - CNBC – “Stock market news for Jan. 23, 2026 – live updates”
https://www.cnbc.com/2026/01/22/stock-market-today-live-updates.html[cnbc] - Trading Economics – “United States Economic Calendar”
https://tradingeconomics.com/united-states/calendar[tradingeconomics] - Investing.com – “7 Critical Signals From This Week’s U.S. Economic Calendar (January 19–23, 2026)”
https://in.investing.com/analysis/7-critical-signals-from-this-weeks-us-economic-calendar-january-1923-2026-200633925[in.investing] - Yahoo Finance – Eli Lilly and Company (LLY) quote page
https://finance.yahoo.com/quote/LLY/[finance.yahoo] - Yahoo Finance – “Why Eli Lilly (LLY) Stock Is Up Today”
https://finance.yahoo.com/news/why-eli-lilly-lly-stock-203040864.html[finance.yahoo] - Motley Fool via AOL – “Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Consider”
https://www.aol.com/articles/eli-lilly-soared-39-2025-103000224.html[aol] - MarketBeat – “Strs Ohio Sells 46,646 Shares of Eli Lilly and Company (LLY)”
https://www.marketbeat.com/instant-alerts/filing-strs-ohio-sells-46646-shares-of-eli-lilly-and-company-lly-2026-01-23/[marketbeat] - Investor’s Business Daily – “Eli Lilly Stock Rebounds As Weight-Loss Drug Battle Continues”
https://www.investors.com/stock-lists/sector-leaders/eli-lilly-stock-lly-orforglipron-weight-loss-drugs/[investors] - Globe and Mail – “4 Leading Tech Stocks to Buy in 2026”
https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/36954814/4-leading-tech-stocks-to-buy-in-2026/[theglobeandmail] - MarketBeat – “Best Technology Stocks To Consider – January 5th”
https://www.marketbeat.com/instant-alerts/best-technology-stocks-to-consider-january-5th-2026-01-05/[marketbeat] - Global X ETFs – “The Next Big Theme: January 2026”
https://www.globalxetfs.com/articles/the-next-big-theme-january-2026[globalxetfs] - Nasdaq.com – “Pre-Markets Lower Ahead of Massive Polar Vortex”
https://www.nasdaq.com/articles/pre-markets-lower-ahead-massive-polar-vortex[nasdaq] - CNBC – “Biggest Wall Street analyst calls Thursday like Nvidia”
https://www.cnbc.com/2026/01/15/biggest-wall-street-analyst-calls-thursday-like-nvidia.html[cnbc] - Yahoo Finance – “High Growth US Tech Stocks To Watch In January 2026”
https://finance.yahoo.com/news/high-growth-us-tech-stocks-113827833.html[finance.yahoo] - Yahoo Finance – “Oil Ticks Up as Trump Cites ‘Framework’ for Greenland Deal”
https://finance.yahoo.com/news/oil-drops-traders-gear-trump-060219587.html[finance.yahoo]
